Cleveland Clinic
Cleveland, Ohio, 44195, United States
NCT Number: NCT03319251
The purpose of this research is to obtain a blood sample from patients with actinic keratoses undergoing routine Photodynamic Therapy, in order to measure biomarkers that are relevant to VitD and 5FU metabolism and might be predictive of PDT outcome. The biomarkers to be examined include serum VitD levels at the time of PDT, and the presence/absence of gene alleles that correlate with expression of several proteins involved in VitD and 5FU metabolism. The presence of these biomarkers will be correlated to the improvement in AK lesion counts at the patient's routine follow-up visit 3 months after PDT treatment.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Cleveland, Ohio, 44195, United States
Patients who have been scheduled to receive PDT in our noninvasive cutaneous oncology clinics will be given written information prior to their visit, including a copy of the Informed Consent (IC) that describes the purpose of the study. If the patient indicates that he/she is interested, the physician or study nurse will review the IC with the patient on the day of PDT and answer all questions. After the patient signs the IC, the patient will have their blood drawn by a caregiver who has completed PTS Phlebotomy Training.
DNA samples will be stored in a locked minus 80 degree ultrafreezer, in Dr. Maytin's laboratory (room ND4-25A in the Lerner Research Institute). The samples will be maintained for up to 10 years.
Blood sample tubes and data sheets in the laboratory will be labeled with a code consisting of the first 5 digits of the patient's 8-digit MRN along with the date that the phlebotomy was performed (i.e. the date of the blood draw). This should ensure anonymity of the data while preventing mistakes when linking the laboratory results to the correct patient. Study personnel with password-protected access to the database registry will use the code to unequivocally identify the subject's file within the Oracle database and thereby enter the subject's laboratory results into the proper data field.
The Informed Consent document informs the subject that he/she can withdraw permission for use of their samples at any time, and explains how to do this by contacting the Principal Investigator (PI) in writing.
Information will not be disclosed to third party outside of Cleveland Clinic for research purposes.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: at 3 months post-treatment
Change in AK lesions present at 3 months post-PDT treatment
Time frame: At baseline, which is the day of PDT treatment
Vitamin D level (25-hydroxy-cholecalciferol) measured in serum
Time frame: At baseline, which is the day of PDT treatment
Identify the allele combination present at VDR locus
Time frame: At baseline, which is the day of PDT treatment
Identify the allele combination present at TS locus
The Cleveland Clinic
Other
Biomarkers of Clinical Responsiveness to Photodynamic Therapy
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06888362
Actinic Keratosis, Keratosis
Uppsala, Sweden
View Trial DetailsNCT06027619
Actinic Keratosis, Keratosis
Cleveland, Ohio, United States
View Trial DetailsNCT06319794
Actinic Keratosis, Keratosis
Basel, Switzerland
View Trial DetailsNCT00472459
Actinic Keratosis, Basal Cell Carcinoma
Aarhus, Denmark
View Trial Details